Genicular Nerve Block in Rheuamtoid Arthritis

Sohag University

Status and phase: Completed; Phase 4

Conditions: Inflammation; Pain; Joint Function Disorder

Treatments: Drug: triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip); Drug: Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)

Study type: Interventional

Funder types: Other

Identifiers

NCT04361513

28/4/2020

Details and patient eligibility

About

N=64 RA patients either early or established disease diagnosed after ACR/EULAR criteria 2010 with unilateral persistent knee arthritis. They were randomly assigned into two groups; group 1 received genicular nerve block, group 2 intra-articular triamcinolone. Both groups were examined by SOLAR scoring system, Visual analogue scale (VAS) and Lysholm score at 0, 2 and 12 weeks. A semi-quantitative score was used to assess tenderness and swelling at the same intervals.

Enrollment: 64 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• RA patients
• Age > 18
• unilateral persistent knee arthritis

Exclusion criteria

• Participants with severe knee osteoarthritis
• peripheral neuropathy
• psoriatic arthritis
• skin infection
• or those who have allergy for Bupivacaine

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

64 participants in 2 patient groups

Nerve block group

Active Comparator group

Description:

3 point genicular nerve block under ultrasound guidance. half ml of Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer) was injected in each point.

Treatment:

Drug: Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)

Drug: triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)

intra-articular steroid injection

Other group

Description:

1 mL of triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) was injected intraarticular.

Treatment:

Drug: Bupivacaine hydrochloride 0.5% (Marcaine, Pfizer)

Drug: triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip)